2024
Rapid Remission of Plaque Psoriasis With Bimekizumab Treatment.
Abdin R, Gharib R, Bunick C, Issa N. Rapid Remission of Plaque Psoriasis With Bimekizumab Treatment. Journal Of Drugs In Dermatology 2024, 23: 694-696. PMID: 39093648, DOI: 10.36849/jdd.8381.Peer-Reviewed Original ResearchConceptsPlaque psoriasisIL-17AIL-17FAnti-IL-17 biologicsSafety of bimekizumabPathogenesis of psoriasisMonoclonal immunoglobulin G1Psoriasis patientsBimekizumabTreatment optionsClinical trialsPsoriasisMedical literatureClearance timeImmunoglobulin G1Rapidity of responseTreatmentPatientsEfficacyClearancePlaqueBrodalumabCytokinesPathogenesisReceptors
2023
Congenital Ichthyosis: A Practical Clinical Guide on Current Treatments and Future Perspectives
Lilly E, Bunick C. Congenital Ichthyosis: A Practical Clinical Guide on Current Treatments and Future Perspectives. Clinical Cosmetic And Investigational Dermatology 2023, 16: 2473-2479. PMID: 37719935, PMCID: PMC10503504, DOI: 10.2147/ccid.s388608.Peer-Reviewed Original ResearchDisease-specific recommendationsPractical clinical guideEye complicationsClinical reviewLongitudinal careGrowth restrictionClinical guideCurrent treatmentDermatological therapyHereditary disorderCongenital ichthyosesOrphan conditionAffected individualsComplicationsTreatmentThermodysregulationPatientsTherapyInfectionKeratinizationCare
2022
Antibiotic Resistance Risk with Oral Tetracycline Treatment of Acne Vulgaris
Swallow MA, Fan R, Cohen JM, Bunick CG. Antibiotic Resistance Risk with Oral Tetracycline Treatment of Acne Vulgaris. Antibiotics 2022, 11: 1032. PMID: 36009899, PMCID: PMC9405006, DOI: 10.3390/antibiotics11081032.Peer-Reviewed Original ResearchAcne vulgarisSevere acne vulgarisAntibiotic resistancePotential side effectsOral tetracyclineGut dysbiosisPatients 9Gastrointestinal upsetRisk of resistanceSide effectsDrug AdministrationTetracycline treatmentSarecyclineTetracycline usageAcneTreatmentTetracyclineAntibiotic resistance riskPathogenic bacteriumRiskVulgarisDizzinessVertigoDysbiosisMinocycline
2020
Structural Basis for How Biologic Medicines Bind their Targets in Psoriasis Therapy.
Eldirany SA, Ho M, Bunick CG. Structural Basis for How Biologic Medicines Bind their Targets in Psoriasis Therapy. The Yale Journal Of Biology And Medicine 2020, 93: 19-27. PMID: 32226331, PMCID: PMC7087057.Peer-Reviewed Original ResearchConceptsBiologic therapyTumor necrosis factor alphaFirst-line treatmentTreatment of psoriasisNecrosis factor alphaClinical responseInterleukin-17Interleukin-23Line treatmentPrescribing practicesPsoriasis therapyInflammatory disordersTreatment optionsTherapeutic decisionsClinical dataFactor alphaPatient safetyTherapySignificant differencesBiologic medicinesDrugsEpitope locationMolecular differencesTreatmentMedications